Compare · ABOS vs GILD
ABOS vs GILD
Side-by-side comparison of Acumen Pharmaceuticals Inc. (ABOS) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABOS and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $185.61B, about 1148.4x ABOS ($161.6M).
- Over the past year, ABOS is up 42.7% and GILD is up 34.0% - ABOS leads by 8.7 points.
- GILD has been more active in the news (10 items in the past 4 weeks vs 2 for ABOS).
- GILD has more recent analyst coverage (25 ratings vs 12 for ABOS).
- Company
- Acumen Pharmaceuticals Inc.
- Gilead Sciences Inc.
- Price
- $2.24+0.22%
- $150.88+0.84%
- Market cap
- $161.6M
- $185.61B
- 1M return
- -25.58%
- +1.86%
- 1Y return
- +42.68%
- +33.98%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 1992
- News (4w)
- 2
- 10
- Recent ratings
- 12
- 25
Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ABOS
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
- Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
- SEC Form S-8 filed by Acumen Pharmaceuticals Inc.
- SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
- Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
- Director Porter Derrell exercised 19,500 shares at a strike of $1.07 and sold $75,240 worth of shares (32,300 units at $2.33), decreasing direct ownership by 27% to 35,500 units (SEC Form 4)
- SEC Form 144 filed by Acumen Pharmaceuticals Inc.
Latest GILD
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
- Chief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 590 shares and covered exercise/tax liability with 285 shares, increasing direct ownership by 4% to 8,759 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,780 shares and covered exercise/tax liability with 4,230 shares, increasing direct ownership by 0.79% to 581,683 units (SEC Form 4)
- Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines